These findings therefore indicate that the Val66Met polymorphism in the BDNF gene could be used as an early determinant on whether patients should be subjected to anti-depression therapies, enabling them to receive such treatment before depressive symptoms appear. Here, BDNF is linked to major depressive disorder.